Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Expert Opinion on Biological Therapy|August 22, 2022
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectivesEugenia Cella, Lodovica Zullo, Silvia Marconi, et al.
Frontiers in Pharmacology|April 6, 2026
Targeted therapies in non-small cell lung cancer and their cardiovascular impact: mechanisms, clinical profiles, and strategies of managementSimone Nardin, Francesca Vezzoli, Gianluca Cognolato, et al.
International Journal of Molecular Sciences|April 3, 2021
Novel Emerging Molecular Targets in Non-Small Cell Lung CancerSara Elena Rebuzzi, Lodovica Zullo, Giovanni Rossi, et al.
Journal of Clinical Medicine|October 5, 2019
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with NivolumabCarlo Genova, Simona Boccardo, Marco Mora, et al.
Cancers|February 26, 2025
Immune Checkpoint Inhibitors and Targeted Therapies in Early-Stage Non-Small-Cell Lung Cancer: State-of-the-Art and Future PerspectivesLucrezia Barcellini, Simone Nardin, Gianluca Sacco, et al.
Cancers|May 6, 2020
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable PatientGiovanni Rossi, Alessandro Russo, Marco Tagliamento, et al.
Lung|March 14, 2024
Circulating Osteopontin Predicts Clinical and Radiological Response in First-Line Treatment of Advanced Non-Small Cell Lung CancerDavide Ramoni, Simona Coco, Giovanni Rossi, et al.
Cancer Research|November 5, 2020
Radiomic Detection of EGFR Mutations in NSCLCGiovanni Rossi, Emanuele Barabino, Alessandro Fedeli, et al.
Frontiers in Immunology|March 3, 2020
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung CancerSelene Ottonello, Carlo Genova, Irene Cossu, et al.
Cancers|July 2, 2021
The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with NivolumabMatteo Bauckneht, Carlo Genova, Giovanni Rossi, et al.
Pageof 9